Adicet Bio (LTS:0HX7) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Adicet Bio's Net Income for the three months ended in Mar. 2024 was $-28.02 Mil. Adicet Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Adicet Bio's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Adicet Bio's Net Margin % or its related term are showing as below:

LTS:0HX7's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -150.095
* Ranked among companies with meaningful Net Margin % only.

Adicet Bio Net Margin % Historical Data

The historical data trend for Adicet Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Net Margin % Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-2,827.94

-204.87

-637.19

-279.27

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Adicet Bio's Net Margin %

For the Biotechnology subindustry, Adicet Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Net Margin % falls into.

Adicet Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Adicet Bio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-142.658	/	0
	=	%

Adicet Bio's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-28.016	/	0
	=	%

Adicet Bio (LTS:0HX7) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Adicet Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (LTS:0HX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines